ALK's Q1 better than predicted on top and bottom line

Allergy firm ALK upgrades its financial outlook for the rest of the year following a first quarter that exceeded expectations.
Photo: ALK / PR
Photo: ALK / PR

Danish pharmaceutical company ALK managed to do better than predicted in the first three months of the year measured by income as well as revenue.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading